Article

Identification of mutation-independent BRCA2 protein deficiency expands diagnostics and selection of pancreatic cancer patients for personalized therapy with PARP1 inhibitors

2024-09-08

Abstract excerpt

<title>Abstract</title> <p><bold>Background: </bold>Recently, therapies involving poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP1) inhibitors have been approved for metastatic BRCA1/2-mutated pancreatic ductal adenocarcinoma (PDAC). The current scheme of identification of patients with BRCA deficiency relies on genetic screening. Here, we tested the hypothesis that pancreatic tumors have a broader spec...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 0c79b3a9-ebec-56d4-b435-084f612543f8
DOI: 10.21203/rs.3.rs-4840364/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Identification of mutation-independent BRCA2 protein deficiency expands diagnostics and selection of pancreatic cancer patients for personalized therapy with PARP1 inhibitorsDOI 10.21203/rs.3.rs-4840364/v1Read

Pancreatic cancer: BRCA mutation and personalized treatment.Semantic proximity Read

Emerging strategies in BRCA-positive pancreatic cancer.Semantic proximity Read

Olaparib Monotherapy for Previously Treated Pancreatic Cancer With DNA Damage Repair Genetic Alterations Other Than Germline BRCA VariantsSemantic proximity Read

Precision Medicine for BRCA/PALB2-Mutated Pancreatic Cancer and Emerging Strategies to Improve Therapeutic Responses to PARP InhibitionSemantic proximity Read

DNA Repair Dysfunction in Pancreatic Cancer: A Clinically Relevant Subtype for Drug Development.Semantic proximity Read

BRCA-Mutated Pancreatic Cancer: From Discovery to Novel Treatment ParadigmsSemantic proximity Read

Overcoming therapeutic resistance in pancreatic cancer: Emerging opportunities by targeting BRCAs and p53Semantic proximity Read

BRCA Mutations in Pancreas Cancer: Spectrum, Current Management, Challenges and Future ProspectsSemantic proximity Read

Molecular characteristics of BRCA1/2 and PALB2 mutations in pancreatic ductal adenocarcinoma.Semantic proximity Read

CRISPR/Cas9-Mediated Knockdown Of BRCA1/2 Restores Response To Olaparib In Pancreatic Cancer Cell LinesSemantic proximity Read

Pancreas cancer and BRCA : A critical subset of patients with improving therapeutic outcomesSemantic proximity Read

BRCA mutations in pancreatic cancer and progress in their targeting.Semantic proximity Read